Regulatory News CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”Cancer advocates express concern about comments that signal trouble for accelerated approval November 07, 2025Vol.51 No.41By Claire Marie Porter and Paul Goldberg
Guest Editorial How George Tidmarsh crossed the FDA-industry Rubicon November 07, 2025Vol.51 No.41By Mikkael A. Sekeres
Cancer Policy Zongertinib, dostarlimab chosen in second batch of National Priority Vouchers recipients November 07, 2025Vol.51 No.41By Jacquelyn Cobb
Drugs & Targets FDA approves Darzalex Faspro for high-risk smoldering multiple myeloma November 07, 2025Vol.51 No.41
Friends publishes three white papers ahead of annual meetingTopics: Clinical trials on rare cancers, combination drug trials, multi-regional studies October 31, 2025Vol.51 No.40By Sara Willa Ernst
Drugs & Targets FDA publishes draft guidance to accelerate biosimilar development and lower costs October 31, 2025Vol.51 No.40
Cancer Policy Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA October 24, 2025Vol.51 No.39By Claire Marie Porter
Regulatory NewsTrials & Tribulations Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research October 17, 2025Vol.51 No.38By Edison T. Liu
News AnalysisRegulatory News How animal testing became a MAHA political wedge issueWhile cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough October 17, 2025Vol.51 No.38By Claire Marie Porter and Jacquelyn Cobb
Drugs & Targets FDA requires a boxed warning for immune effector cell-associated enterocolitis following Carvykti treatment October 17, 2025Vol.51 No.38
